A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment- Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Research Grant
Administered By
Ophthalmology
Awarded By
Adverum Biotechnologies, Inc
Start Date
May 17, 2022
End Date
March 31, 2029
Administered By
Ophthalmology
Awarded By
Adverum Biotechnologies, Inc
Start Date
May 17, 2022
End Date
March 31, 2029